Epigenetics in the Development of Alzheimer’s Disease
1 Medicine and Nutrition Faculty Juarez University of Durango State. Durango, Dgo., México, downton aerea.
2 Genetic Department. Medicine and Nutrition Faculty Juarez University of Durango State, Durango, Dgo., México.
Review Article
GSC Advanced Research and Reviews, 2024, 19(03), 156–163.
Article DOI: 10.30574/gscarr.2024.19.3.0208
Publication history:
Received on 30 April 2024; revised on 10 June 2024; accepted on 12 June 2024
Abstract:
Alzheimer's Disease (AD), a cause of dementia, has emerged as a significant public health concern that affects societies worldwide. Statistics of 2021 reveal that there are 55 million reported cases of this disease globally, this disease is characterized by the gradual deterioration of nerve cells in the brain, which inevitably leads to a decline in cognitive abilities.
The progression of AD is significantly influenced by genetic factors. Scientific research has helped identify over 40 genetic risk loci that are associated with the disease, giving an idea on the molecular mechanisms behind its development. However, environmental factors and epigenetic modifications, which are changes in gene expression not caused by alterations in the DNA sequence, also play important roles in the disease's development and progression. The current treatment strategies for AD primarily aim to manage the symptoms and slow the rate of cognitive decline, but these treatments are not curative and the disease continues to progress. This underlines the importance of early diagnosis, which can significantly improve the effectiveness of these treatments. Decoding the role of genetics and epigenetics in the development of AD is key to identifying potential therapeutic targets and developing effective treatments. The understanding of these factors will provide valuable insights into the pathophysiology of AD, contributing to advancements in medical research and healthcare strategies aimed at combating the disease.
Keywords:
Alzheimer; Genetics; Epigenetics; Healthcare; Neurodegenerative
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
